688317 Stock Overview
Engages in the research and development, production, and sale of molecular genetic diagnostic reagents, instruments, and equipment in China. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 2/6 |
Shanghai ZJ Bio-Tech Co., Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥18.73 |
52 Week High | CN¥24.06 |
52 Week Low | CN¥12.58 |
Beta | 0.59 |
11 Month Change | 8.71% |
3 Month Change | 17.43% |
1 Year Change | -19.79% |
33 Year Change | -63.99% |
5 Year Change | n/a |
Change since IPO | -74.99% |
Recent News & Updates
Recent updates
Shareholder Returns
688317 | CN Medical Equipment | CN Market | |
---|---|---|---|
7D | -1.7% | -5.6% | -6.7% |
1Y | -19.8% | -10.2% | 1.9% |
Return vs Industry: 688317 underperformed the CN Medical Equipment industry which returned -10.2% over the past year.
Return vs Market: 688317 underperformed the CN Market which returned 1.9% over the past year.
Price Volatility
688317 volatility | |
---|---|
688317 Average Weekly Movement | 7.6% |
Medical Equipment Industry Average Movement | 8.6% |
Market Average Movement | 8.2% |
10% most volatile stocks in CN Market | 12.5% |
10% least volatile stocks in CN Market | 5.5% |
Stable Share Price: 688317 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688317's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 286 | Junbin Shao | www.liferiver.com.cn |
Shanghai ZJ Bio-Tech Co., Ltd. engages in the research and development, production, and sale of molecular genetic diagnostic reagents, instruments, and equipment in China. The company was founded in 2005 and is based in Shanghai, China.
Shanghai ZJ Bio-Tech Co., Ltd Fundamentals Summary
688317 fundamental statistics | |
---|---|
Market cap | CN¥3.56b |
Earnings (TTM) | -CN¥184.51m |
Revenue (TTM) | CN¥206.71m |
17.2x
P/S Ratio-19.3x
P/E RatioIs 688317 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
688317 income statement (TTM) | |
---|---|
Revenue | CN¥206.71m |
Cost of Revenue | CN¥242.94m |
Gross Profit | -CN¥36.23m |
Other Expenses | CN¥148.28m |
Earnings | -CN¥184.51m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.97 |
Gross Margin | -17.53% |
Net Profit Margin | -89.26% |
Debt/Equity Ratio | 0% |
How did 688317 perform over the long term?
See historical performance and comparison